FactSet Guides FY21 Adj. EPS In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter and fiscal 2020 on Thursday, FactSet Research Systems, Inc. (FDS) initiated earnings and revenue outlook for the full-year 2021.

For fiscal 2021, the company now expects earnings in a range of $10.05 to $10.45 per share and adjusted earnings in a range of $10.75 to $11.15 per share on revenue between $1.570 billion and $1.585 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $10.84 per share on revenues of $1.55 billion for the year. Analysts' estimates typically exclude special items.

"While the global environment continues to be uncertain as we head into 2021, we remain confident in our ability to operate productively and invest successfully during this challenging period," said Helen Shan, FactSet CFO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT